Nanobiotix S.A. (NASDAQ:NBTX - Get Free Report) shares fell 2% during mid-day trading on Tuesday . The company traded as low as $3.75 and last traded at $3.95. 27,386 shares traded hands during mid-day trading, an increase of 61% from the average session volume of 17,058 shares. The stock had previously closed at $4.03.
Analyst Upgrades and Downgrades
Separately, UBS Group raised Nanobiotix to a "hold" rating in a research note on Monday, February 17th.
Check Out Our Latest Stock Analysis on NBTX
Nanobiotix Trading Down 5.1 %
The business has a fifty day moving average price of $3.33 and a two-hundred day moving average price of $4.13.
Hedge Funds Weigh In On Nanobiotix
A number of hedge funds have recently modified their holdings of the business. Millennium Management LLC purchased a new position in shares of Nanobiotix during the 4th quarter worth $39,000. Jane Street Group LLC purchased a new position in shares of Nanobiotix during the 4th quarter worth $73,000. Geode Capital Management LLC purchased a new position in shares of Nanobiotix during the 4th quarter worth $29,000. Finally, OLD Mission Capital LLC purchased a new position in Nanobiotix during the 4th quarter valued at about $139,000. 38.81% of the stock is currently owned by hedge funds and other institutional investors.
About Nanobiotix
(
Get Free Report)
Nanobiotix SA, a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer.
Further Reading
Before you consider Nanobiotix, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Nanobiotix wasn't on the list.
While Nanobiotix currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
